Beractanto

Beractanto is the active substance of a pulmonary surfactant medicine known commercially as Survanta.

This drug, for intratracheal use, is indicated for the treatment of newborn children with respiratory distress syndrome, since its action increases the elasticity of the lung and improves its functioning.

Beractanto is produced by the Abbott laboratory.

Indications of Beractanto

Beractanto is indicated for the prophylaxis and treatment of respiratory distress syndrome, also called hyaline membrane disease in neonates and premature infants.

How to use Beractanto

The mode of use of Beractanto consists of the administration of 100 mg per kg in newborn infants, intratracheally.

Treatment should be started as early as possible. In prevention it should be started at least 15 minutes after childbirth and in the rescue before completing 8 hours of life.

Four doses of the drug can be given within the first 48 hours of life, at intervals of 6 hours to 12 hours.

Beractanto Side Effects

The side effects of Beractanto may be decreased heart rate, decreased blood oxygen concentration, decreased brain electrical activity, and increased risk of pulmonary hemorrhage.

Contraindications of Beractanto

It has no specific contraindications.